Now showing items 1-1 of 1

  • ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. 

    Feldinger, K; Generali, D; Kramer-Marek, G; Gijsen, M; Ng, TB; Wong, JH; Strina, C; Cappelletti, M; Andreis, D; Li, J-L; Bridges, E; Turley, H; Leek, R; Roxanis, I; Capala, J; Murphy, G; Harris, AL; Kong, A (United States, 2014-08-30)
    Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV